Summary of Community Decisions on marketing authorisations in respect of medicinal products from 15 April 1999 to 15 May 1999

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ([1]))

(1999/C 180/02)

— Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community register	Date of notification
7.5.1999	Procomvax	Pasteur Mérieux MSD 8, rue Jonas Salk F-69007 Lyon	EU/1/99/104/001	14.5.1999
7.5.1999	Rebetol	Schering Plough Europe 73, rue de Stalle B-1180 Bruxelles	EU/1/99/107/001-003	17.5.1999

— Modification of a marketing authorisation (Article 12 of Regulation (EEC) No 2309/93) Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community register	Date of notification
11.5.1999	Betaferon	Schering Aktiengesellschaft Pharma D-13342 Berlin	EU/1/95/003/001-002	31.5.1999
11.5.1999	Bondronat	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/96/012/001-004	18.5.1999
11.5.1999	Xenical	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/98/071/001-006	18.5.1999
11.5.1999	Xenical	Roche Registration Limited 40 Broadwater Road Welwyn Garden City Hertfordshire AL7 3AY United Kingdom	EU/1/98/071/001-006	18.5.1999
11.5.1999	Optruma	Eli Lilly Nederland BV Krijtwal 17-23 3432 ZT Nieuwegen Nederland	EU/1/98/074/001-004	18.5.1999
11.5.1999	Comtess	Orion Corporation Orionintie 1 FIN-02200 Espoo	EU/1/98/082/001-004	16.5.1999

([1]) OJ L 214, 24.8.1993, page 1.

— **Modification of a marketing authorisation (Article 34 of Regulation (EEC) No 2309/93)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community register	Date of notification
11.5.1999	Nobilis	Intervet International BV 35 Wim de Körverstraat 5831 AN Boxmeer Nederland	EU/2/98/006/009-010	18.5.1999

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions realting thereto is invited to contact:

The European Agency for the Evaluation of Medicinal Products
7, Westferry Circus, Canary Wharf
London E14 4HB
United Kingdom

Summary of Community Decisions on marketing authorisations in respect of medicinal products from 15 May 1999 to 15 June 1999

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93 ([1]))

(1999/C 180/03)

— **Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)**

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community register	Date of notification
18.5.1999	Comtess	Orion Corporation Orionintie 1 FIN-02200 Espoo	EU/1/98/082/001-004	26.5.1999
28.5.1999	Stocrin	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	EU/1/99/111/001-004	7.6.1999
28.5.1999	Sustiva	DuPont Pharmaceuticals Limited Wedgwood Way Stevenage Hertfordshire SG1 4QN United Kingdom	EU/1/99/110/001-004	7.6.1999
2.6.1999	Exelon	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 4AB United Kingdom	EU/1/98/066/013	11.6.1999

([1]) OJ L 214, 24.8.1993, p. 1.